Global Action Fund for Fungal Infections

The Global Action Fund for Fungal Infections (GAFFI), is an international foundation focussed on
raising awareness of and collecting worldwide data on fungal disease. Its aim is to make reliable and Global Action Fund for Fungal
inexpensive diagnostic tests widely available. Infections

In 2015, GAFFI proposed action to make afforable fungal diagnostic tests and antifungal treatments
available to 95% of the world's population by 2025. In 2018 GAFFI calculated that globally around one
billion people have fungal infections of the skin, more than one million people become blind from fungal
keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more
than 300 million people have a severe fungal infection every year, of whom over 1.5 million die.

Contents
Location and members
Aims
Activities
Abbreviation GAFFI
References
Purpose
Raise awareness of
and collect data on
Location and members fungal disease[1]
To make reliable
GAFFI is based in Switzerland and the United Kingdom.[3] Its chief executive is David Denning, professor
and inexpensive
of Infectious Diseases and Global Health at the University of Manchester, UK.[3][4] Emma Orefuwa is one
diagnostic tests
of its executives,[5] and also chief executive of GAFFI Kenya.[6] Its advisors include Arunaloke Chakrabarti
widely available[2]
from India[7][8] as well as individuals from the United States, Australia, Spain, Norway, Brazil and
Japan.[7] Fields Fungal disease
Chief David Denning[3]
Aims executive
Website Official website (https://
GAFFI is an international foundation focussed on raising awareness of and collecting worldwide data on gaffi.org)
[1]
fungal disease. Its aim is to get reliable and inexpensive diagnostic tests to be widely available,
particularly in low and middle income countries.[2] The tests can be produced but the increasing cost of regulatory approval causes difficulty in
getting them from the experimental stage in the laboratory to real world use in clinics.[2]

Activities
GAFFI collects data on fungal diseases.[9][10]

GAFFI was launched in India in 2014.[7] In 2015, diagnostic tests and antifungal treatments were available for 33-50% of people with severe
fungal disease.[11] That year GAFFI proposed action to make fungal diagnostic tests and antifungal treatments available to 95% of the world's
population by 2025.[12] Six actions were proposed:

Provide rapid diagnostic tests that do not rely on culture, and that are affordable.[12][13]
Establish at least one laboratory in each country, led by fungal disease experts.[12]
Create clinical guidelines and teaching programmes.[12]
Better distribute antifungal medicines on the WHO Model List of Essential Medicines.[12]
Establish fungal infection surveillance systems.[12]
Invest in public health mycology.[12]

In 2018 GAFFI calculated that globally around one billion people have fungal infections of the skin, more than one million people become blind
from fungal keratitis, more than 10 million people develop lung disease after breathing in fungal spores, and more than 300 million people have a
severe fungal infection every year, of which over 1.5 million will die from it.[14][15] It met with the World Health Organization (WHO) prior to the
WHO advisory meeting in April 2018 and the launch of the WHO's first WHO list of essential diagnostic tests.[16]

References
1. Buitrago, Maria J.; Valero, Clara (2020). "4. Laboratory diagnosis of
histoplasmosis: an update". In Bongomin, Felix (ed.). Histoplasma
and Histoplasmosis (https://www.google.co.uk/books/edition/Histopl
asma_and_Histoplasmosis/qpUtEAAAQBAJ?hl=en&gbpv=1&dq=W
HO+Essential+Diagnostics+gaffi&pg=PA58&printsec=frontcover).
London: BoD – Books on Demand. p. 58. ISBN 978-1-83962-961-7.
2. Gadd, Geoffrey M.; Sariaslani, Sima (2020). Advances in Applied
Microbiology (https://www.google.co.uk/books/edition/Advances_in_
Applied_Microbiology/M-PgDwAAQBAJ?hl=en&gbpv=1&dq=gaffi+f
ungi&pg=PA39&printsec=frontcover). Elsevier. pp. 39-
40language=en. ISBN 978-0-12-820703-1.
3. "Professor David Denning" (https://bsac.org.uk/speakers/professor-
david-denning/). The British Society for Antimicrobial
Chemotherapy. Retrieved 14 August 2021.
 4. Khalaj, Vahid (September 2018). "Professor David W. Denning an
Extraordinary High Achiever in Clinical and Translational Science"
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058189/). Iranian
Biomedical Journal. 22 (5): 290–291. ISSN 1028-852X (https://ww
w.worldcat.org/issn/1028-852X). PMID 29397044 (https://pubmed.n
cbi.nlm.nih.gov/29397044).
5. "Executive - Gaffi | Gaffi - Global Action Fund for Fungal Infections"
(https://web.archive.org/web/20210820113616/https://gaffi.org/who/
executive-advisors/). gaffi.org. Archived from the original (https://gaf
fi.org/who/executive-advisors/) on 20 August 2021. Retrieved
20 August 2021.
6. "Board of Directors – PAMCA" (https://web.archive.org/web/202108
20113239/https://pamca.org/board-of-directors/). Archived from the
original (https://pamca.org/board-of-directors/) on 20 August 2021.
Retrieved 20 August 2021.
7. "GAFFI | International experts gather in Delhi to convene a global
NGO to fight fungal infections that kill 150 people every hour" (http
s://www.realwire.com/releases/International-experts-gather-in-Delhi
-to-convene-a-global-NGO). RealWire. 7 January 2014. Retrieved
14 August 2021.
8. "Senior Advisors - Gaffi | Gaffi - Global Action Fund for Fungal
Infections" (https://web.archive.org/web/20210820112617/https://ga
ffi.org/who/senior-advisors/). gaffi.org. Archived from the original (ht
tps://gaffi.org/who/senior-advisors/) on 20 August 2021. Retrieved
20 August 2021.
9. Chander J (2018). "1. Introduction" (https://books.google.com/book
s?id=OLpEDwAAQBAJ&pg=PA8). Textbook of Medical Mycology
(4th ed.). New Delhi: Jaypee Brothers Medical Publishers Ltd. p. 8.
ISBN 978-93-86261-83-0.
10. "Global Action Fund for Fungal Infections" (https://www.ntd-ngonet
work.org/global-action-fund-for-fungal-infections). NNN. Retrieved
14 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Global_Action_Fund_for_Fungal_Infections&oldid=1040921433"
This page was last edited on 27 August 2021, at 13:30 (UTC).
11. Bremer, Steve (8 May 2015). "Call for global action on fungal
infection" (https://pharmaceutical-journal.com/article/opinion/call-for
-global-action-on-fungal-infection). The Pharmaceutical Journal.
doi:10.1211/PJ.2015.20068514 (https://doi.org/10.1211%2FPJ.201
5.20068514).
12. Denning, David W. (1 July 2015). "The ambitious '95–95 by 2025'
roadmap for the diagnosis and management of fungal diseases" (ht
tps://thorax.bmj.com/content/70/7/613). Thorax. 70 (7): 613–614.
doi:10.1136/thoraxjnl-2015-207305 (https://doi.org/10.1136%2Fthor
axjnl-2015-207305). ISSN 0040-6376 (https://www.worldcat.org/iss
n/0040-6376).
13. Gadd, Geoffrey M.; Sariaslani, Sima (June 2020). Advances in
Applied Microbiology (https://www.google.co.uk/books/edition/Adva
nces_in_Applied_Microbiology/M-PgDwAAQBAJ?hl=en&gbpv=1&d
q=gaffi+fungi&pg=PA39&printsec=frontcover). Elsevier. p. 39.
ISBN 978-0-12-820703-1.
14. Rodrigues, Marcio L.; Nosanchuk, Joshua D. (20 February 2020).
"Fungal diseases as neglected pathogens: A wake-up call to public
health officials" (https://journals.plos.org/plosntds/article?id=10.137
1/journal.pntd.0007964). PLOS Neglected Tropical Diseases. 14
(2): e0007964. doi:10.1371/journal.pntd.0007964 (https://doi.org/10.
1371%2Fjournal.pntd.0007964). ISSN 1935-2735 (https://www.worl
dcat.org/issn/1935-2735). PMID 32078635 (https://pubmed.ncbi.nl
m.nih.gov/32078635).
15. Rao, Venketeshwer; Mans, Dennis; Rao, Leticia (12 February
2020). Phytochemicals in Human Health (https://www.google.co.uk/
books/edition/Phytochemicals_in_Human_Health/5pj8DwAAQBAJ?
hl=en&gbpv=1&dq=gaffi+fungi&pg=PA238&printsec=frontcover).
BoD – Books on Demand. p. 238. ISBN 978-1-78985-587-6.
16. "WHO Releases its first essential diagnostic list" (http://life-worldwid
e.org/media-centre/article/who-releases-its-first-essential-diagnostic
-list). life-worldwide.org. Retrieved 20 August 2021.
Text is available under the Creative Commons Attribution-ShareAlike License;
additional terms may apply. By using this site, you agree to the Terms of Use and Privacy
Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.